Author

Marie-Elise Beydon

Observed name: M. E. Beydon

Institution: mAbxience Holding, S.L. (Spain)

Observed institution: mAbxience Holding, S.L. (Spain)

ORCID: 0000-0002-0085-1740

Observed ORCID: 0000-0002-0085-1740

OpenAlex ID: A5091270711

Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization

2022 · Isabel Ruppen, Marie-Elise Beydon, et al. · Biologicals · 10

Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization

2021 · Isabel Ruppen, Marie-Elise Beydon, et al. · Biologicals · 7

A randomized, double‐blind, single‐dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab

2023 · C. Schwabe, A. Cole, et al. · Pharmacology Research & Perspectives · 2

Analytical Similarity Assessment of Bevacizumab Biosimilar MB02 Using Multiple State-of-the-art Assays

2021 · Daniel Sacristan, Marie-Elise Beydon, et al. · 2

Characterization of mAb size heterogeneity originating from a cysteine to tyrosine substitution using denaturing and native LC-MS

2023 · Isabel Ruppen, Liesa Verscheure, et al. · Journal of Pharmaceutical and Biomedical Analysis

Analytical Similarity Assessment of Bevacizumab Biosimilar Candidate MB02 Using Multiple State-of-the-art Assays

2021 · Marie-Elise Beydon

Works count: 6

Citation count: 21

H-index: 2

I10-index: 1